drugset / Trial / NCT04472806
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Phase 2
Unknown
31 enrolled
Fudan University
Fujian Cancer Hospital · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or Metastatic Mucosal Melanoma.
Timeline
- Start
- 2020-06-20
- Primary completion
- 2022-06-20
- Completion
- 2023-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
| Background | Endostar | Protein / enzyme biologic | — | — |